Visual Dysfunction in Diabetes The Science of Patient Impairment and Health Care

Introduction

Diabetic Retinopathy – what we know, don’t know, and need to know – Tom Gardner

Living with Diabetic Retinopathy

Ch. 1 A Patient’s viewpoint: Heather Stuckey

Ch. 2 What patients with diabetes see—and don’t see: subjective and objective visual function

changes - Shelly Boyd

Ch. 3 How do I know I have diabetic retinopathy – a clinician’s view? - David Quillen

Prevalence, Public Awareness, and Screening Methods

Ch. 4 Epidemiology & Economics - John Javitt

Ch. 5 Correlation between the presence and severity of diabetic retinopathy in families with diabetes

- Victor Gonzalez

Ch. 6 Increasing public awareness of the diabetes endemic – Ian Constable

Ch. 7 Nutrition and diabetes– David Nathan

Ch. 8 Diabetic retinopathy screening – progress and complications - Peter Scanlon

Diagnosing Diabetic Retinopathy

Ch. 9 Measurements of retinal blood flow, vascular leakage, and oxygenation – Einer Stefansson

Ch. 10 Optical imaging - Confocal microscopy to detect retinal vasculature – Martin Friedlander

Ch. 11 Structural imaging – OCT – M. Larsen

Ch. 12 Functional imaging - ERG - Anthony Adams

How Diabetes Affects the Eye

Ch. 13 Clinical phenotypes (reclassification) – J. Cunha-Vaz

Ch. 14 Vascular changes – David Antonetti & Tom Gardiner (Belfast)

Ch. 15 Neuronal ch

Ch. 16 Inflammatory changes - Mark Tso

Ch. 17 Other Ocular Complications of Diabetes - Shoja MR

New Approaches to Diabetic Retinopathy

Ch. 18 New insights in the pathogenesis of diabetic retinopathy using a proteomic approach – Retina -

Quin GG

Ch. 19 Vitreous proteomics – Ed Feener

Ch. 20 Genomics - Bill Freeman

Ch. 21 Genome-wide linkage analyses to identify Loci for diabetic retinopathy - Kang Zhang (Utah)

Risk Factors

Ch. 22 Diabetic retinopathy correlates with increased incidence of cardiovascular events -Cheung N

Ch. 23 Pregnancy and rate of progression of diabetic retinopathy – Sheth BP

Molecular Mechanisms that Could Trigger Visual Dysfunction in Diabetes

Introduction - Tom Gardner

Ch. 24 Inflammation in the early pathogenesis of diabetic retinopathy —beauty and beast. - Chris Norbury (Hershey)

Ch. 25 Oxidative stress and diabetic retinopathy. - Catherine Whiteside

Ch. 26 Glucose induced cellular signaling in diabetic retinopathy – Chakrabarti S

Ch. 27 The AGE/RAGE axis in early diabetic retinopathy - Schmidt AM

Ch. 28 Proteases and the retinal vasculature (and maybe the whole retina!) – Arup Das.

Ch. 29 IGFBP3 and retinal vessel growth. Smith LE

Ch. 30 PEDF, VEGF, CTGF review – JX Ma

Ch. 31 A decrease in the expression of somatosta

Carrasco E

Ch. 32 Connective tissue and connective tissue growth factor in diabetic retinopathy - Schlingemann

RO

Ch. 33 Molecular regulation of endothelial cell tight junctions and the blood retinal barrier - Antonetti

DA

Ch. 34 Pericytes and diabetic retinopathy - Puro DG

Ch. 35 Leukostasis - Adamis, AP

Ch. 36 Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes. -

Khalfaoui T,

Ch. 37 Azurocidin as a Permeability Factor in the Retina - Hafezi-Moghadam A

Ch. 38 Retinal arteriolar hemodynamic response to a combined isocapnic hyperoxia and glucose

provocation in early sight-threatening diabetic retinopathy. - Devenyi RG.

Ch. 39 Urinary 8-hydroxydeoxyguanosine (8-OHdG) levels in diabetic retinopathy patients. - Steve

Abcouwer

Ch. 40 Tyrosine nitration in the molecular mechanisms of diabetic retinopathy. - Crabb JW

Limiting Vision Loss - Experimental Therapies

Introduction - Tom Gardner

Vascular Control

Ch. 41 Ranibizumab for macular edema in diabetes – Quan Dong Nguyen

Ch. 42 Bevacizumab for PDR - Qin H

Ch. 43 Capillary degeneration in the early stages of diabetic retinopathy. Kern TS

Ch. 44 Renin-angiotensin system in the eye - Jennifer Wilkinson-Berka

Ch. 45 Statins and the BRB –Ruth Caldwell

Neuro

Ch. 46 Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a

mouse model of disease. Lahdenranta J

Ch. 47 Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in

Early Diabetes - Zhang J and Xu GT

Inflammatory Control

Ch. 48 Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic

retinopathy. Sawada N

Ch. 49 Ruboxistaurin shows promise as an oral treatment for diabetic retinopathy - Clarke M, Dodson

PM.

Ch. 50 Intravitreal triamcinolone acetonide for diabetic retinopathy - Jonas JB

Ch. 51 Aptamers that bind PDGF-B are a potential treatment for proliferative retinopathies. Akiyama H

Ch. 52 Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy - Lin J

Regenerative Approaches

Ch. 53 Islet Cell/stem cell transplantation - Warnock GL (Canada)

Future Directions

Ch. 54 How do we improve the translational research process? What do we need to know? Barbara

Araneo

Conclusion – Tom Gardner